-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Immunovant, Raises Price Target to $50

Benzinga·08/04/2026 18:40:43
语音播报
JP Morgan analyst Brian Cheng maintains Immunovant (NASDAQ:IMVT) with a Overweight and raises the price target from $47 to $50.